TrialThe Lancet. Oncology2023

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.

Stephen R D Johnston et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.